Adherium sells its 100,000th Smartinhaler
Digital health company Adherium is celebrating a significant milestone, having recently manufactured and sold its 100,000th Smartinhaler.
Smartinhalers are electronic sensors that attach to a patient’s prescription inhaled medicine. Once attached, the Smartinhaler automatically tracks medication usage and reminds the patient to take their medication as prescribed. They also automatically upload the electronic medication usage to a smartphone app where the patient or caregiver can review their usage, and to a web portal for population health management.
The Smartinhaler platform has so far been supplied to more than 40 countries, used in more than 65 projects (clinical, device validation or other) and referenced in over 70 peer-reviewed articles published in journals such as Thorax and The Lancet Respiratory Medicine. Clinical outcomes data has shown that the platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults, leading to improved quality of life and demonstrating a gain over current best practice treatment.
“The sale of our 100,000th Smartinhaler shows that Adherium’s commercial rollout is accelerating,” said Adherium CEO Arik Anderson. “It is one thing to design Smartinhalers, but a whole different matter to manufacture and sell this number of devices.”
Adherium was last month announced as a finalist in the OBN Awards 2017, which celebrate innovation and achievement across the UK life sciences industry. The company was shortlisted in the category ‘Best Implementation of Digital Healthcare’ for providing smart personal medication monitoring systems, in the form of the Smartinhaler, to help patients manage their chronic respiratory conditions.
“Being shortlisted for this award is a huge honour, and testament to our team and our technology,” said Anderson. “The Smartinhaler platform is built on years of research and has been extensively validated in both UK and mainland European studies. We have partnered with AstraZeneca to combine our technology with their inhaler medications, to help enable improvements in patient health and reduce the significant costs associated with non-adherence.”
The award winners will be announced at the 9th OBN Annual Awards evening, to be held at Oxford Town Hall on 5 October.
Softer tumours fuel spread of triple-negative breast cancer
A metabolic 'survival switch' controlled by the stiffness of triple-negative breast...
Maternal protein intake affects offspring's facial features
New study findings emphasise the importance of maintaining a well-balanced diet during pregnancy,...
Gene discovery offers hope for new kidney disease treatments
Researchers have identified a gene that plays a crucial role in regulating energy supply to cells...
